Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Freek J. Janssen is active.

Publication


Featured researches published by Freek J. Janssen.


Journal of Lipid Research | 2015

A natural substrate-based fluorescence assay for inhibitor screening on diacylglycerol lipase α

Tom van der Wel; Freek J. Janssen; Marc P. Baggelaar; Hui Deng; Hans den Dulk; Herman S. Overkleeft; Mario van der Stelt

The endocannabinoid 2-arachidonoylglycerol (2-AG) is predominantly biosynthesized by sn-1-diacylglycerol lipase α (DAGL-α) in the CNS. Selective inhibitors of DAGL-α will provide valuable insights in the role of 2-AG in endocannabinoid signaling processes and are potential therapeutics for the treatment of obesity and neurodegenerative diseases. Here, we describe the development of a natural substrate-based fluorescence assay for DAGL-α, using a coupled enzyme approach. The continuous setup of our assay allows monitoring of DAGL-α activity in real-time and in a 96-well plate format. This constitutes a major improvement to the currently available radiometric and LC/MS-based methods, which can be executed only in low-throughput formats. In addition, our assay circumvents the use of radioactive material. We demonstrate that our assay can be used to screen inhibitors of DAGL-α activity, using 1-stearoyl-2-arachidonoyl-sn-glycerol as the physiologically relevant natural substrate of DAGL-α. Furthermore, our method can be employed to measure DAGL activity and inhibition in the mouse brain membrane proteome. Consequently, our assay should serve as a valuable tool for rapid hit validation and lead optimization of DAGL-α inhibitors.


Journal of Medicinal Chemistry | 2017

Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding

Hui Deng; Sander Kooijman; Adrianus M. C. H. van den Nieuwendijk; Daisuke Ogasawara; Tom van der Wel; Floris van Dalen; Marc P. Baggelaar; Freek J. Janssen; Richard J. B. H. N. van den Berg; Hans den Dulk; Benjamin F. Cravatt; Herman S. Overkleeft; Patrick C. N. Rensen; Mario van der Stelt

Triazole ureas constitute a versatile class of irreversible inhibitors that target serine hydrolases in both cells and animal models. We have previously reported that triazole ureas can act as selective and CNS-active inhibitors for diacylglycerol lipases (DAGLs), enzymes responsible for the biosynthesis of 2-arachidonoylglycerol (2-AG) that activates cannabinoid CB1 receptor. Here, we report the enantio- and diastereoselective synthesis and structure-activity relationship studies. We found that 2,4-substituted triazole ureas with a biphenylmethanol group provided the most optimal scaffold. Introduction of a chiral ether substituent on the 5-position of the piperidine ring provided ultrapotent inhibitor 38 (DH376) with picomolar activity. Compound 38 temporarily reduces fasting-induced refeeding of mice, thereby emulating the effect of cannabinoid CB1-receptor inverse agonists. This was mirrored by 39 (DO34) but also by the negative control compound 40 (DO53) (which does not inhibit DAGL), which indicates the triazole ureas may affect the energy balance in mice through multiple molecular targets.


Journal of Medicinal Chemistry | 2015

Comprehensive Analysis of Structure–Activity Relationships of α-Ketoheterocycles as sn-1-Diacylglycerol Lipase α Inhibitors

Freek J. Janssen; Marc P. Baggelaar; Jessica Hummel; Herman S. Overkleeft; Benjamin F. Cravatt; Dale L. Boger; Mario van der Stelt

Diacylglycerol lipase α (DAGLα) is responsible for the formation of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the central nervous system. DAGLα inhibitors are required to study the physiological role of 2-AG. Previously, we identified the α-ketoheterocycles as potent and highly selective DAGLα inhibitors. Here, we present the first comprehensive structure-activity relationship study of α-ketoheterocycles as DAGLα inhibitors. Our findings indicate that the active site of DAGLα is remarkably sensitive to the type of heterocyclic scaffold with oxazolo-4N-pyridines as the most active framework. We uncovered a fundamental substituent effect in which electron-withdrawing meta-oxazole substituents increased inhibitor potency. (C6-C9)-acyl chains with a distal phenyl group proved to be the most potent inhibitors. The integrated SAR data was consistent with the proposed binding pose in a DAGLα homology model. Altogether, our results may guide the design of future DAGLα inhibitors as leads for molecular therapies to treat neuroinflammation, obesity, and related metabolic disorders.


Bioorganic & Medicinal Chemistry Letters | 2016

Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic disorders

Freek J. Janssen; Mario van der Stelt

2-Arachidonoylglycerol (2-AG) is an endocannabinoid that activates the cannabinoid receptors type 1 and 2. It also serves as an important lipid precursor for the eicosanoid signaling pathway. Consequently, 2-AG is involved in many physiological functions, including anxiety, food intake, inflammation, memory, pain sensation and neurotransmission. Diacylglycerol lipases (DAGLs) are the main biosynthetic enzymes for 2-AG and their role in several pathophysiological conditions is currently under investigation. In this Digest we review all DAGL inhibitors reported to date and their effects in preclinical models of neurodegeneration and metabolic disorders.


Angewandte Chemie | 2013

Development of an Activity‐Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipase‐α in Brain

Marc P. Baggelaar; Freek J. Janssen; Annelot C. M. van Esbroeck; Hans den Dulk; Marco Allarà; Sascha Hoogendoorn; Ross McGuire; Bogdan I. Florea; Nico J. Meeuwenoord; Hans van den Elst; Gijsbert A. van der Marel; Jaap Brouwer; Vincenzo Di Marzo; Herman S. Overkleeft; Mario van der Stelt


Journal of the American Chemical Society | 2015

Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons

Marc P. Baggelaar; Pascal Chameau; Vasudev Kantae; Jessica Hummel; Ku-Lung Hsu; Freek J. Janssen; Tom van der Wel; Marjolein Soethoudt; Hui Deng; Hans den Dulk; Marco Allarà; Bogdan I. Florea; Vincenzo Di Marzo; Wytse J. Wadman; Chris G. Kruse; Herman S. Overkleeft; Thomas Hankemeier; Taco R. Werkman; Benjamin F. Cravatt; Mario van der Stelt


Journal of Medicinal Chemistry | 2014

Discovery of glycine sulfonamides as dual inhibitors of sn-1-diacylglycerol lipase α and α/β-hydrolase domain 6.

Freek J. Janssen; Hui Deng; Marc P. Baggelaar; Marco Allarà; Tom van der Wel; Hans den Dulk; Alessia Ligresti; Annelot C. M. van Esbroeck; Ross McGuire; Vincenzo Di Marzo; Herman S. Overkleeft; Mario van der Stelt


Angewandte Chemie | 2013

Innenrücktitelbild: Development of an Activity-Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipase-α in Brain (Angew. Chem. 46/2013)

Marc P. Baggelaar; Freek J. Janssen; Annelot C. M. van Esbroeck; Hans den Dulk; Marco Allarà; Sascha Hoogendoorn; Ross McGuire; Bogdan I. Florea; Nico J. Meeuwenoord; Hans van den Elst; Gijsbert A. van der Marel; Jaap Brouwer; Vincenzo Di Marzo; Herman S. Overkleeft; Mario van der Stelt


MedChemComm | 2017

Chiral disubstituted piperidinyl ureas: a class of dual diacylglycerol lipase-α and ABHD6 inhibitors

Hui Deng; Tom van der Wel; Richard J. B. H. N. van den Berg; Adrianus M. C. H. van den Nieuwendijk; Freek J. Janssen; Marc P. Baggelaar; Hermen S. Overkleeft; Mario van der Stelt


Archive | 2016

Composés pharmaceutiquement actifs à titre d'inhibiteurs de lipases dag

Der Stelt Mario Van; Freek J. Janssen; Marc P. Baggelaar; Jessica Hummel

Collaboration


Dive into the Freek J. Janssen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge